Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Air quality expert wins 2025 PM's Prize for Science
Distinguished Professor Lidia Morawska's work in the study of air quality provided vital...
CSL fellowships fund immunity research, AI-designed proteins
Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL...
Leukaemia Foundation funds ongoing blood cancer research at UWA
The $3m in funding is understood to represent the single largest non-government investment in...
